Quantitative proteomics of different zones in human articular cartilage reveals early changes of protein distribution in preclinical knee osteoarthritis  by Khabut, A. et al.
Abstracts / Osteoarthritis and Cartilage 21 (2013) S63–S312 S271changed to serum-free labeling medium containing also chondrogenic
inducers. Expression of cartilage speciﬁc genes such as type I and II
collagen and proteoglycans were used to verify the chondrogenicity of
hBMSCs. Proteins in the CM harvested on day 2 and 14 of differentiation
were precipitated and combined at a 1:1 ratio. Each mixture was then
separated by 1D-SDS-PAGE and subjected to in-gel trypsin digestion
using an automatic digester. The resulting peptide mixtures were
analyzed by nanoscale liquid chromatography coupled on-line to an
LTQ-Orbitrap XLmass spectrometer and quantiﬁed using the MaxQuant
software.
Results: A progressive increase of type II collagen, agreccan and chon-
droitin-6-sulfate during the course of 14 days of differentiation was
detected by immunohistochemical assays, suggesting that hMSCs
maintain their chondrogenic capacity in SILAC medium. Using the
metabolic labeling strategy, we compared the secretomes at two
different time points of chondrogenesis. More than 1000 proteins were
identiﬁed with high conﬁdence parameters. 20% of them were previ-
ously known ECM-related proteins. Among these, 34 exhibited
a signiﬁcant modulation of their levels during the process of chondro-
genesis, including cartilage ECM proteins such as COMP, lumican, pro-
largin, ﬁbromodulin and matrix gla protein (MGP), which could be
involved in the organization and/or stabilization of cartilage matrix. All
these proteins were increased at day 14 of chondrogenesis. Finally,
pentraxin-related protein (PTX3), which plays a role in the regulation of
inﬂammatory response, resulted decreased at day 14.
Conclusions: This study was focused on characterizing the speciﬁc
modulations in the secretome of hBMSCs undergoing chondrogenesis
using the SILAC method. The identiﬁcation and quantiﬁcation of these
secreted proteins provide information about the changes in the ECM
synthesis during the differentiation process. Moreover, these ﬁndings
enhance our knowledge of extracellular regulation of this process and
allow the identiﬁcation of extracellular markers of chondrogenesis,
which might have potential value in cartilage regeneration strategies.
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ANTI-ANGIOGENIC ACTION OF CHONDROITIN SULFATE: A NOVEL
TARGET FOR OSTEOARTHRITIS THERAPY
V. Calamia y, J. Mateos y, P. Fernandez-Puente y, L. Lourido y, B. Rocha y,
C. Fernandez-Costa y, E. Montell z, J. Vergés z, C. Ruiz-Romero y, F.J.
Blanco y. yOsteoarticular and Aging Res. Lab., Proteomics Unit-Associated
Node to ProteoRed-ISCIII, INIBIC-CHUAC, A Coruña, Spain; z Pre-clinical
R&D Area, Pharma Sci. Div., Bioibérica, Barcelona, Spain
Purpose: Recent works by our group provide evidences of the useful-
ness of proteomics techniques for anti- osteoarthritis (OA) drug
screening. The aim of this study is to identify protein markers for
monitoring chondroitin sulfate (CS) treatment by OA chondrocytes
secretome analysis using the iTRAQ technique.
Methods:Human articular chondrocytes (HACs) released from three OA
cartilages were cultured in DMEM supplemented with antibiotics and
10% FBS. At conﬂuence, OA chondrocytes were treated with 200 mg/mL
of CS (100% purity, bovine origin). 48 hours later, conditioned media
were collected and their proteins were concentrated and quantiﬁed.
Trypsin digestion and labeling with isobaric tags using iTRAQ reagents
were performed. Then, peptides from the two conditions (untreated,Table 1
Left panel: proteins increased by CS. Right panel: proteins decreased by CS.
Protein name Ratio p Value
Aggrecan core protein 1,57 0
Annexin A1 2,08 0,0144
Annexin A2 1,31 0,0365
Annexin A5 1,50 0,0091
Coiled-coil domain-containing
protein 80
1,77 0,0001
Connective tissue growth factor 1,84 0,0009
Extracellular sulfatase Sulf-1 2,11 0,0402
Glia-derived nexin 1,73 0
Hyaluronan and proteoglycan
link protein 1
1,74 0,0028
Target of Nesh-SH3 1,61 0,0019
Tenascin 1,71 0
Thrombospondin-1 1,90 0
Vascular cell adhesion protein 1 1,44 0,0039and CS-treated) were mixed, separated by reversed-phase liquid chro-
matography (LC) and analyzed by nanoscale reversed-phase LC coupled
to mass spectrometry (nLC-MALDI-MS/MS). The identiﬁcation and
quantiﬁcation of proteins (by calculating the different iTRAQ tag
intensities for each peptide) was carried out with Protein Pilot 4.0
software. Real-time, western blot, and immunohistochemistry analyses
were performed to validate our results.
Results: Database search (UniprotKB/Swissprot) allowed the identiﬁ-
cation of 260 different proteins secreted by OA chondrocytes. Among
them, we found 23 secreted proteins presenting statistically signiﬁcant
differences in abundance (p0.05) between treated and untreated
samples: 13 were increased by CS treatment and 10were decreased (see
Table 1). We considered only those proteins with a probability score
higher than 95%, a ratio 1.3 or -1.3, and an error factor <2. We have
successfully quantiﬁed the increase of extracellular matrix components
like aggrecan and other proteoglycans, and the decrease of degradative
enzymes such as cathepsins, caused by the administration of CS.
Annexins were increased by the drug while a glycolytic enzyme was
decreased. Finally we found altered several proteins involved in cell
adhesion and angiogenesis; among them we observed a strong CS-
dependent increase of an angiogenesis inhibitor, thrombospondin-1
(TSP1). Owing to the pivotal role of angiogenesis in OA physiopathology,
we decided to verify TSP1 gene expression level in CS-treated chon-
drocytes by real time-PCR analysis. TSP1 protein level was also veriﬁed
in chondrocyte conditioned media (secretome) and cellular extracts
(proteome) by western blot analyses, and in cartilage explants by
immunohistochemistry. The results obtained in the validation experi-
ments conﬁrmed the proteomics data.
Conclusions: We have found that isobaric tags using iTRAQ reagents is
one of the most promising strategies for accurate comparative proteo-
mics using HACs. We have generated a quantitative proﬁle of chon-
drocyte extracellular protein changes driven by CS in OA.
Demonstration of the anti-angiogenic action of CS might provide
a novel therapeutic approach for OA targeting. This study, however, has
been limited to an in vitro system. In the next futurewe hope to ﬁnd the
altered secreted proteins circulating in serum of OA patients treated
with CS.
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QUANTITATIVE PROTEOMICS OF DIFFERENT ZONES IN HUMAN
ARTICULAR CARTILAGE REVEALS EARLY CHANGES OF PROTEIN
DISTRIBUTION IN PRECLINICAL KNEE OSTEOARTHRITIS
A. Khabut y, C. Müller z, A. Aspberg x, J. Dudhia k, D. Heinegård y,
P. Önnerfjord y. yClinical Sci., Lund, Sweden; zDept. of Biology,
Copenhagen, Denmark; xDept. of Biology, Copenhagen, Dominica; kVet.
Clinical Sci., London, United Kingdom
Purpose: The progress in proteomics technology development during
the last decade has contributed novel tools for detailed studies of the
composition of tissue extracellular matrix at the protein level including
cartilage and bone. We have used quantitative proteomics for a detailed
study of different zones in articular cartilage to increase our knowledge
of structure in relation to biology and function. In this work we studied
changes in protein abundance in very early osteoarthritic articular knee
cartilage samples in comparison to normal tissue.Protein name Ratio pValue
Alpha-actinin-4 -1,36 0,0338
Calreticulin -2,03 0,0144
Cathepsin D -1,34 0,0462
Cathepsin L1 -1,44 0,0251
Heat shock protein HSP 90-beta -1,77 0,0415
Moesin -1,50 0,038
Protein S100-A6 -1,98 0,0153
Pyruvate kinase isozymes M1/M2 -1,43 0,002
Retinol-binding protein 4 -1,44 0,026
Vimentin -1,42 0,0016
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digestion by trypsin and reversed phase separations coupled to tandem
mass spectrometry for the identiﬁcation and targeted quantiﬁcation of
peptides by multiple reaction monitoring (MRM). The tissue was sliced
from synovial surface to bone in 10mm thin sections and the full
thickness cartilage was divided into 100mm pools including superﬁcial,
intermediate and deep zones.
Results: Previous known distribution of proteoglycan 4 (PRG4, lubricin,
superﬁcial zone protein) was conﬁrmed but also novel ﬁndings were
observed e.g. asporin which was predominantly present in the super-
ﬁcial layers. In total 40 proteins were quantiﬁed showing distinct
patterns in normal tissue. In addition we observed altered protein
distribution patterns in preclinical (macroscopically normal) tissue
from a joint with early ﬁbrillation (OA-lesions) on the opposite surface.
Conclusions: As an alternative to immunohistochemistry we used
proteomics technology to study the protein abundance across full
thickness articular cartilage. The advantages of this approach are that it
allows multiple targets to be studied simultaneously, it is independent
of antibody availability and circumvent some antibody-related artifacts.
Other advantages include unambiguous identiﬁcations and improved
quantiﬁcations. The work shows novel information on the differences
that exist in different layers of cartilage that is of value in understanding
changes in early pathology.
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HIGH-THROUGHPUT PROTEOMIC ANALYSIS OF THE CARTILAGE
SECRETOME FOR IDENTIFICATION OF INFLAMMATORY BIOMARKERS
A. Williams y, J. Smith z, D. Allaway x, P. Harris x, S. Liddell y,
A. Mobasheri y. yUniv. of Nottingham, Sutton Bonington, United
Kingdom; zBruker UK Limited, Coventry, United Kingdom; xWALTHAM
Ctr. for Pet Nutrition, Waltham-on-the-Wolds, United Kingdom
Purpose: Biomarkers of cartilage inﬂammation and degradation can
provide information about the pathogenesis of arthritic diseases such as
osteoarthritis (OA), allowing earlier diagnosis, improved monitoring,
and mechanistic insight into OA progression. Utilizing high-throughput
proteomics approaches, this study aimed to identify and quantitatively
compare proteins that respond to pro-inﬂammatory (IL-1b) and anti-
inﬂammatory (carprofen) stimuli in the secretome of articular cartilage.
Methods: Articular cartilage was harvested from equine meta-
carpophalangeal joints from horses euthanized for purposes other than
research. Explant cultures were established and treated as follows:
untreated (control) media alone, pro-inﬂammatory cytokine IL-1b (10
ng/ml), the COX-2 speciﬁc non-steroidal anti-inﬂammatory drug
(NSAID) carprofen (100 mg/ml) or IL-1b + carprofen. After 6 days incu-
bation (37C, 5% CO2) media were collected for downstream analysis,
using a combination of SDS-PAGE, silver staining, high-throughput
nanoLC-MS/MS on an amaZon speed ETD (Bruker) and quantitative
western blotting.
Results: High-throughput mass spectrometry identiﬁed cartilage
extracellular matrix (ECM) proteins (biglycan, ﬁbronectin, decorin,
COMP, collagen type II), secreted proteins related to cartilage mainte-
nance and turnover (MMP-1, -3 and -13, TIMP-1), along with inﬂam-
matory stress/molecular chaperone related proteins (HSP70, clusterin).
Qualitative differences in PCPE-2, frizzled related protein, HSP70, MMP-
1, -3 and -13 release were observed between untreated and cytokine
treated explant secretomes. Quantitative analysis by western blotting
conﬁrmed that carprofen treatment signiﬁcantly reduced IL-1b stimu-
lated release of MMP-1, -3 and -13. ECM proteins targeted by these
IL-1b-stimulated MMPs (i.e. ﬁbronectin) exhibited additional frag-
mentation patterns on western blots, which were reduced by carprofen
treatment.
Conclusions: Proteins differentially released in response to IL-1b
stimulationwithin this explant model may enable screening of new and
existing drugs and various natural compounds with anti-inﬂammatory
properties. This study revealed that carprofen, a COX-2 speciﬁc inhib-
itor, decreases the release of inﬂammatory-associated proteins and one
established BIPEDS marker of cartilage degradation in OA (MMP-3).
Carprofen-suppression of IL-1b-stimulated MMP-1, -3 and -13 release
may result in reduced ECM degradation indicating that this drug may
potentially reduce progression of degenerative cartilage loss and OA.
This interpretation of the data is supported by the reduction of IL-1b
stimulated ﬁbronectin degradation fragments released from the ECM.
Combining high-throughput analytical techniques such as proteomics
with this in vitro model of cartilage inﬂammation producesinterpretable data and may provide realistic alternatives to in vivo
animal models.530
DISCOVERY OF CARTILAGE-CHARACTERISTIC BIOMARKERS OF
OSTEOARTHRITIS BY QUANTITATIVE PROTEOMICS
L. Lourido, V. Calamia, P. Fernández-Puente, J. Mateos, B. Rocha,
C. Fernández, F.J. Blanco, C. Ruiz-Romero. Osteoarticular and Aging
Res. Lab., Proteomics Unit-Associated Node to ProteoRed-ISCIII, INIBIC-
CHUAC, A Coruña, Spain
Purpose: Osteoarthritis (OA) is characterized by the loss of structural
components from the extracelullar matrix (ECM) of articular cartilage.
The release of these proteins from the tissue can vary according to the
stage of the disease. The aim of this study was to perform a proteomics
approach to identify and quantify those proteins released from normal
and OA human articular cartilage explants. Furthermore, we seeked to
differentiate those proteomic signatures displayed from the wounded
zones (WZ) from those corresponding to the area adjacent to the lesion,
or unwounded zones (UZ), in the OA samples. These proteins released
from cartilage might have a tissue-characteristic biomarker value for
early diagnosis and/or therapy monitoring.
Methods: Macroscopically articular cartilage was obtained from the
dissection of normal and OA femoral heads. The cartilage from normal
samples, and from WZ and UZ of the same OA piece, was cut into ﬁve
6mm2 explants. Then, these explants were washed in PBS and har-
vested in 96-well plates with 200mL of serum-free DMEM. The condi-
tioned media from each condition were collected at days 1, 3, 6 and
replaced with fresh medium. Media from each condition were quanti-
ﬁed, concentrated and precipitated O/N with acetone. Finally, proteins
were digested with trypsin and each peptide solution was labelled with
different isobaric tags using the iTRAQ reagents. The labelled peptides
of the different conditions weremixed, desalted and separated by HPLC.
The resulting fractions were grouped and resolved by reversed-phase
nanoliquid cromatography coupled to mass spectrometry. The identi-
ﬁcation and relative quantiﬁcation of the proteins was carried out with
Protein Pilot 3.0 software.
Results: Protein concentrations were higher in the culture media from
wounded zones than from unwounded zones of OA cartilage, due to the
increased degradation that is taking place in the lesion. We ﬁrst identi-
ﬁed several ECM proteins that were differentially released betweenWZ
and UZ in OA samples at two different times of culture. Most of them
were increased in the wounded tissue, including collagens (I, II, VI and
XV), proteoglycans (biglycan, lumican or perlecan) and proteins related
with cell adhesion (tenascins, osteomodulin or vitronectin). In a second
step, proteins released to themedia up today6of culturewere compared
between three conditions (WZ, UZ and normal tissue). This analysis led
to the identiﬁcation of 199 proteins, 110 of them quantitatively altered
between the conditions of the study. Interestingly, several proteinswere
differentially released already in the unwounded zone of OA cartilage
compared to the normal samples (osteopontin, matrilin-3, cartilage link
protein or transforming growth factor-beta-induced protein), and their
amounts do not seem to be increased in the WZ. Finally, a small set of
proteins, including thrombospondin-1 or type XVIII collagen,weremore
abundant in the media from N cartilage than from OA.
Conclusions: We have identiﬁed a proﬁle of proteins released from
diseased cartilage in OA. Our work describes a panel of cartilage-char-
acteristic proteins with potential biomarker value of the tissue degra-
dation process that takes place in the disease. This panel will be further
explored in biological ﬂuids (synovial ﬂuid and serum) for the devel-
opment of early diagnosis and/or therapy monitoring strategies.
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SAMPLE CLASSIFICATION AND IDENTIFICATION OF BIOMARKERS IN
THE CARTILAGE SECRETOME FROM MASS SPECTROMETRY
DATASETS USING MACHINE LEARNING
A.L. Swan y, K. Hillier y, J.R. Smith z, D. Allaway x, S. Liddell y,
A. Mobasheri y, J. Bacardit k. yUniv. of Nottingham, Sutton Bonington,
United Kingdom; zBruker UK Limited, Coventry, United Kingdom;
xWALTHAM Ctr. for Pet Nutrition, Waltham-on-the-Wolds, United
Kingdom; kUniv. of Nottingham, Nottingham, United Kingdom
Purpose: The aim of this study was to develop bioinformatic methods
for the identiﬁcation of a minimum set of biomarkers present in the
